HeartBeam Navigates Telehealth Market with Stable $4 Analyst Target
HeartBeam, Inc. (NASDAQ:BEAT), a medical technology company focused on cardiac telehealth solutions, has maintained a stable consensus analyst price target of $4 over the past year. In a more optimistic projection, Industrial Alliance Securities has set a price target of $10 for the company.
The Santa Clara-based firm, established in 2015, specializes in a compact electrocardiogram device and a cloud-based diagnostic system. The company's engagement with the financial community was noted in recent earnings calls. The Q2 2025 call on August 13, 2025, and the Q1 2025 call on May 13, 2025, included participation from analysts at The Benchmark Company and Joseph Gunnar, respectively.
Future valuation for HeartBeam is expected to be influenced by product innovations, market expansion, and potential partnerships with healthcare providers. As a medical technology company, its growth is also closely linked to regulatory approvals for new products or features, which can significantly affect the company's valuation.
Further details on the company are available regarding its history and ownership, mission and vision, financial health, and its investor profile.
HeartBeam, Inc. (BEAT) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.